Sientra Stock Forecast, Price & News

0.00 (0.00 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume444,343 shs
Average Volume785,260 shs
Market Capitalization$474.54 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SIEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Sientra and its competitors with MarketBeat's FREE daily newsletter.

Sientra logo

About Sientra

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States and internationally. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.81 out of 5 stars

Analyst Opinion: 2.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Sientra (NASDAQ:SIEN) Frequently Asked Questions

Is Sientra a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sientra stock.
View analyst ratings for Sientra
or view top-rated stocks.

What stocks does MarketBeat like better than Sientra?

Wall Street analysts have given Sientra a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sientra wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sientra's next earnings date?

Sientra is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Sientra

How can I listen to Sientra's earnings call?

Sientra will be holding an earnings conference call on Tuesday, August 10th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Sientra's earnings last quarter?

Sientra, Inc. (NASDAQ:SIEN) released its earnings results on Tuesday, May, 11th. The medical instruments supplier reported ($1.01) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.73. The medical instruments supplier had revenue of $23.24 million for the quarter, compared to analysts' expectations of $18.23 million. Sientra had a negative trailing twelve-month return on equity of 901.29% and a negative net margin of 149.62%.
View Sientra's earnings history

How has Sientra's stock price been impacted by Coronavirus (COVID-19)?

Sientra's stock was trading at $2.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SIEN shares have increased by 238.1% and is now trading at $8.25.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SIEN?

4 equities research analysts have issued twelve-month price targets for Sientra's stock. Their forecasts range from $8.24 to $11.00. On average, they expect Sientra's share price to reach $9.75 in the next year. This suggests a possible upside of 18.1% from the stock's current price.
View analysts' price targets for Sientra
or view top-rated stocks among Wall Street analysts.

Who are Sientra's key executives?

Sientra's management team includes the following people:
  • Ms. Caroline F. Van Hove, Exec. Chair of Board of Directors (Age 40, Pay $197.74k)
  • Mr. Ronald Menezes, Pres, CEO & Director (Age 59, Pay $650.01k)
  • Mr. Oliver Christian Bennett, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 44, Pay $363.5k)
  • Mr. Keith J. Sullivan, Director & Advisor to MiraDry Bus. (Age 63, Pay $40k)
  • Ms. Valerie J. Miller, Interim CFO, VP & Corp. Controller (Age 57)
  • Mr. Jeffrey S. Jones, VP of Operations (Age 65)
  • Ms. Deborah Bettencourt, VP of HR & Corp. Admin.
  • Mr. Kirk Gunhus, Sr. VP of Worldwide Sales
  • Ms. Lisa Rosas, VP of Marketing

Who are some of Sientra's key competitors?

What other stocks do shareholders of Sientra own?

What is Sientra's stock symbol?

Sientra trades on the NASDAQ under the ticker symbol "SIEN."

Who are Sientra's major shareholders?

Sientra's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Kornitzer Capital Management Inc. KS (0.29%). Company insiders that own Sientra stock include Hove Caroline F Van, Jeffrey M Nugent, Oliver Christian Bennett, Paul Sean Little and Valerie J Miller.
View institutional ownership trends for Sientra

Which major investors are buying Sientra stock?

SIEN stock was bought by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS.
View insider buying and selling activity for Sientra
or or view top insider-buying stocks.

How do I buy shares of Sientra?

Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sientra's stock price today?

One share of SIEN stock can currently be purchased for approximately $8.25.

How much money does Sientra make?

Sientra has a market capitalization of $474.54 million and generates $71.24 million in revenue each year. The medical instruments supplier earns $-89,950,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Sientra have?

Sientra employs 255 workers across the globe.

What is Sientra's official website?

The official website for Sientra is

Where are Sientra's headquarters?

Sientra is headquartered at 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117.

How can I contact Sientra?

Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.